Chondrocyte and cartilage extracellular matrix

Chondrocytes are specialized, metabolically active cells that originate from mesenchymal stem cells and constitute roughly 2% of articular cartilage volume[1][5]. Their primary function is to synthesize, organize, and remodel the cartilage extracellular matrix (ECM), which comprises over 90% of cartilage by volume and consists mainly of type II collagen, aggrecan, and other proteoglycans, as well as water[2][3]. The ECM is structured into pericellular, territorial, and interterritorial regions, all contributing to cartilage's unique mechanical properties such as resilience, load-bearing, and lubrication[1][3]. The ECM also stores and regulates growth factors relevant to tissue maintenance and repair[4]. Chondrocyte dysfunction or ECM degradation underlies diseases like osteoarthritis, where an imbalance of matrix synthesis and breakdown leads to progressive loss of cartilage structure and function[2][4]. Neither chondrocyte nor cartilage extracellular matrix is a single, conventional therapeutic target (such as a receptor or enzyme); instead, they are functional tissue/cell types or compartments with many potential molecular targets within them. Therefore, this entry—“Chondrocyte and cartilage extracellular matrix”—is not a precise molecular target and should not be treated as such.

Other names

Chondrocyte–cartilage ECMCartilage extracellular matrixChondrocytes

null (see above—drugs interact with specific proteins of cartilage ECM or influence chondrocyte activity rather than "the target" as a combined unit)